The Toxicology and Pharmacology Branch (T&PB) of the Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute is the focus for obtaining and evaluating preclinical toxicology and pharmacology data on anti-cancer and anti-HIV drugs and biologicals that have been approved for NCI development by the DCTD Drug Development Group and the RAID Program. The T&PB also collaborates with the NCI Divisions of Basic (DBS) and Clinical (DCS) Sciences in their drug development programs; the NIH Clinical Center PET Department in the development of imaging agents; with NIAID in the development of drugs to treat AIDS and Opportunistic Infections; and with NICHHD in the development of microbicides for the prevention of AIDS. The ultimate goal is to support an Investigational New Agent Application (IND) or a Drug Master File (DMF) with the USFDA.
The T&PB and it's predecessors have been involved in drug development of cancer drugs since 1955 when the Cancer National Service Center (CNSC) Program was created; in the development of AIDS Drugs since1986; cancer biologicals since 1992; cancer and to a more limited extent, AIDS vaccines since 1993; cancer gene therapy since 1995; and diagnostic imaging agents since 1996. A complete listing of INDs and or DMFs that the T&PB has supported since 1986 is attached (see link below).
CONTACTS
If you wish to contact the Branch to discuss drug development with one of it's pharmacologists and /or toxicologists:
| Phone: | 301-496-8777 | |
| Fax: | 301-480-4836 | |
| Email: | ncidtptpbinfo@mail.nih.gov |
DETAILS
For a more detailed view of information about T&PB's functions, structure, methods, contractors, etc., please click on one of the links below: